Malaria Vaccines Market, By Agent Type (Plasmodium Falciparum, Plasmodium Vivax, and Anopheles Species), By Vaccine Type (Pre-Erythrocytic Vaccine, Erythrocytic Vaccine, and Multi-antigen Vaccine), By Distribution Channel (Hospitals, Clinics, and Community Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Increasing rates of malaria in tropical areas

The primary driver of the market's growth rate is now the rise in malaria prevalence in tropical areas. Female Anopheles mosquitoes spread the potentially fatal infectious disease malaria caused by the Plasmodium parasite. The growth of the target market is anticipated to be driven by the facilitation of the malaria epidemic and the enhancement of mosquito-borne disease viability due to climate change.

For example, the World Health Organization estimates that there were about 229 million cases of malaria in 2019 and 409,000 fatalities, leading to an increase in demand for malaria vaccines. Malaria has primarily plagued tropical regions, such as Africa, Asia, Central America, and South America. In addition, the Western Pacific, Southeast Asia, Africa, and the Eastern Mediterranean have the highest prevalence of malaria.

Infrastructure for healthcare is being more and more funded.

The market growth rate for malaria vaccines is largely driven by the increased investment in healthcare, which also helps to strengthen the infrastructure in that sector. The financing provided by different government agencies and their initiatives to fortify the healthcare infrastructure by spurring market expansion will also influence the market dynamics. The target market will rise due to factors such as the aging population and the increased emphasis on vaccine development. The demand for malaria vaccines will also grow due to increasing patient awareness levels, government initiatives, and the use of vaccinations in more therapeutic contexts.

For example, India's medicines regulator approved the export of a malaria vaccine developed by the Jenner Institute in September 2022. Researchers at the University of Oxford produced it in the United Kingdom, and Serum Institute produced it in the United Kingdom. 409 youngsters participated in the vaccine experiment, which showed that protection against malaria requires three initial doses followed by a booster dose.